Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2007

01-03-2007 | Editorial

Con: Sentinel Lymph Node Biopsy for DCIS. The Breast Surgeon is not a Barber

Author: Henry Mark Kuerer, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 3/2007

Login to get access

Excerpt

I can not remember the last time I went to the barber and did not get a haircut. After all, you go to a barber—you get a haircut. You go to a surgeon doing breast surgery and you get a sentinel lymph node (SLN) biopsy? We are not barbers ladies and gentleman, and not every patient undergoing breast surgery should receive a SLN biopsy. The list of reasons to do a SLN biopsy seems to be endless: if you have ductal carcinoma in situ (DCIS), if you have a chance on an excisional biopsy that there might be cancer, if you had a preneoadjuvant chemotherapy SLN biopsy that showed metastases, if you are receiving prophylactic mastectomy, if you have an in-breast cancer recurrence, and even if you have a clinically palpable axillary lymph node before surgery.1‐6 …
Literature
1.
Kuerer HM, Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 2005; 8:1698–705CrossRef
2.
Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology (Huntingt) 1998: 12:1283–92
3.
Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 4:516–26CrossRef
4.
Specht MC, Fey JV, Borgen PI, Cody HS 3rd. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg 2005; 1:10–14CrossRef
5.
Khan A, Sabel MS, Ness A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol 2005; 9:697–704CrossRef
6.
Port ER, Fey J, Gemignan ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002; 2:167–72CrossRef
7.
Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309–13. PubMedCrossRef
Metadata
Title
Con: Sentinel Lymph Node Biopsy for DCIS. The Breast Surgeon is not a Barber
Author
Henry Mark Kuerer, MD, PhD, FACS
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9159-9

Other articles of this Issue 3/2007

Annals of Surgical Oncology 3/2007 Go to the issue

Letter

Letter to the Editor

OriginalPaper

Role of the BRAF Mutations in the Microsatellite Instability Genetic Pathway in Sporadic Colorectal Cancer

OriginalPaper

Clinical Characteristics and Surgical Outcome in Hepatocellular Carcinoma without Hepatitis B Virus Surface Antigen or Hepatitis C Virus Antibody

OriginalPaper

Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy

Gastrointestinal Oncology

Emergency Room Presentation of Colorectal Cancer: A Consecutive Cohort Study

EditorialNotes

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis